Skip to main content
Daniel Chen, MD, Oncology, Burlingame, CA

DanielS.ChenMDPhD

Oncology • Burlingame, CA

Hematologic Oncology, Melanoma

Founder and CEO, Synthetic Design Lab, Inc Founder, Engenuity Life Sciences

Join to view full profile

Dr. Chen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Chen's full profile

Already have an account?

Summary

  • Cancer Immunotherapy, PD-L1, PD-1, Immunology, Drug Development, Biomarkers, Angiogenesis, Molecular Diagnostics, Biochips, Virology, Targeted Therapy, Melanoma Oncology
    Specialties: Drug Development, Molecular Diagnostics, Translational Research
    Medical Oncologist and Cancer Immunologist.

Education & Training

  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2000 - 2003
  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1998 - 2000
  • Keck School of Medicine of the University of Southern California
    Keck School of Medicine of the University of Southern CaliforniaClass of 1998
  • Massachusetts Institute of Technology
    Massachusetts Institute of TechnologyBS, Biology, 1986 - 1990

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1999 - 2024

Awards, Honors, & Recognition

  • https://www.pinterest.com/dschen5/dsc/

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Differential Regulation of PD-L1 Expression by Immune and Tumor Cells in NSCLC and the Response to Treatment with Atezolizumab (Anti–PD-L1)  
    Alan Sandler, David S Shames, Hartmut Koeppen, Jamie Chaft, Scott N Gettinger, Alexander Spira, Daniel S Chen, Naiyer A Rizvi, David R Spigel, Proceedings of the National Academy of Sciences
  • Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial  
    Fehrenbacher, L, Spira, A, Ballinger, M, Kowanetz, M, Vansteenkiste, J, Mazieres, J, Park, K, Smith, D, Artal-Cortes, A, Lewanski, C, Braiteh, F, Waterkamp, D, He, P, ..., Lancet, 1/1/2016

Abstracts/Posters

  • High Avidity IgM-Based CD20xCD3 Bispecific Antibody (IGM-2323) for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release
    Daniel Chen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

  • Too Many Trials, Not Enough Patients
    Too Many Trials, Not Enough PatientsNovember 18th, 2019
  • Drug Giant Tries New Tactic to Fight Cancer
    Drug Giant Tries New Tactic to Fight CancerMay 27th, 2019
  • A Cure for Cancer: How to Kill a Killer
    A Cure for Cancer: How to Kill a KillerNovember 4th, 2018
  • Join now to see all

Committees

  • Co-Organizer, SITC Immuno Engineering Initiative 2022 - Present
  • co-organizer, SITC Deep Dive Series 2020 - Present
  • Board of Directors, SITC (Society of Immunotherapy for Cancer) 2018 - 2022
  • Co-Chair, CRI Cancer Immunotherapy Consortium 2016 - 2020
  • Committee Chair, Society for Immunotherapy of Cancer 2012 - 2018

Professional Memberships

Other Languages

  • Chinese (Mandarin)

Industry Relationships

  • Founder, Bionic Cell Medicines2022 - Present
  • Founder and CEO, Synthetic Design Lab2022 - Present
  • Founder, Engenuity Life Sciences2022 - Present
  • Chief Medical Officer, IGM Biosciences2018 - Present
  • Vice President, Global Head for Cancer Immunotherapy, Genentech/Roche2006 - 2018

External Links

  • LinkedInhttps://www.linkedin.com/in/daniel-chen-m-d-ph-d-4653842/
  • Pinteresthttps://www.pinterest.com/dschen5/dsc/

Dr. Daniel Chen, Dr. Daniel Chen, MD, Dr. D Chen, Dr. Daniel S. Chen